Nick is an accomplished leader and executive in life sciences with over 25 years of experience in industry, equity research and investment banking. Extensive cross-functional expertise in operational and financial management, strategic planning, business development, investor relations, cross-border M&A and capital raising.

Before being appointed CEO of AusCann, Nick held several senior industry roles previously, including CEO of Perth-based biotech company, Proteolytics; Chief Business Officer of SUDA Pharmaceuticals (ASX:SUD); Chief Financial Officer of Phylogica (ASX:PYC); and Chief Business Officer of UK-based biopharmaceutical company, Oxford BioMedica (LSE:OXB). He began his career as a healthcare investment banker and was formerly head of European biotech equity research at ABN Amro.

Nick is a Fellow Member of the Association of Chartered Certified Accountants; a Graduate of the Australian Institute of Company Directors; holds a Graduate Certificate in Management (with Distinction) from the Australian Institute of Business; and has a BA (Hons) and MA in Chemistry from Oxford University.